Infliximab Safety

NewsGuard 100/100 Score

Infliximab is a medication used to reduce the symptoms and signs of several chronic inflammatory disorders. It is approved for the treatment of Crohn’s disease, rheumatoid arthritis, psoriasis, ankylosing spondylitis and psoriatic arthritis. Infliximab is also known by the trade name Remicade.

Image Credit: F8 studio / Shutterstock
Image Credit: F8 studio / Shutterstock

Infliximab is a monoclonal antibody that has been specifically designed to target the cytokine tumor necrosis factor-alpha (TNF-α). This cell signalling protein plays an important role in the abnormal immune response that occurs in inflammatory disorders. Excess production of TNF-α can lead to inflammation that damages the bones, cartilage and other bodily tissues. Infliximab works by blocking the action of TNF-α, thereby suppressing the immune system and reducing inflammation and the associated symptoms.

Due to the effect of infliximab on the immune system, patients receiving the treatment are susceptible to infections, including severe ones such as sepsis and tuberculosis (TB). Pre-treatment screening is therefore essential for patients and doctors will need to know about the following:

  • Any recent exposure to TB or whether the patient has not received a BCG vaccination. If a patient has not received this vaccination, they may need to undergo a chest X-ray to check for underlying TB before treatment with infliximab can be started. Many doctors now use a blood test to check for TB prior to administering infliximab.
  • Any history of HIV, hepatitis B or C or contact with individuals who have these infections. A blood sample is usually taken to check for these infections before infliximab therapy is initiated.
  • History of living in any region where certain fungal conditions such as coccidioidomycosis or histoplasmosis. Examples of these regions are parts of the USA, Africa and south America.
  • Any history of cancer, since alteration of immune system function may slightly increase the risk of certain forms of cancer.
  • Any current infection. Therapy may need to be postponed until the infection is treated.
  • Any contact with individuals who have chickenpox, measles, shingles, or pneumococcal disease. If a patient is not already immune, they may need to be vaccinated against these infections before treatment is started.

A doctor will also need to know about any history of heart problems because infliximab can worsen symptoms. Patients with heart problems will therefore need close monitoring both before and after infliximab therapy. The use of infliximab can also increase the risk of lung cancer and a physician will need to be informed if the patient is a smoker or has chronic obstructive pulmonary disease.

During therapy

Patients are monitored at all stages while they are receiving an infliximab infusion and for around two hours afterwards to check for signs of allergic reaction. Once a patient has begun their treatment programme, they will continue to be checked regularly to prevent complications or ensure any complications that do develop are caught at an early stage.

Patients are advised to try and avoid coming into contact with anyone who has an infection. Even a mild infection such as a sore throat or cold can turn into a more serious illness when patients are taking this drug. People receiving infliximab also need to be aware of any new symptoms that develop and must tell their doctor if they start to feel unwell or think they may have caught an infection. Doctors also advise that patients take care when preparing food and to avoid eating any undercooked meat or raw eggs, for example. Patients are advised to have an annual flu vaccine while receiving infliximab therapy.

Interaction with other medications

Infliximab has been found to interact with several other medications. Some examples of the drugs that may interact with infliximab include the following:

  • Anakinra
  • Azathioprine
  • 6-mercaptopurine
  • Abatacept
  • Methotrexate

Patients should also advise their doctor of any over-the-counter medications, vitamins, herbal remedies or alternative medicines they are taking.


It is not yet clear whether alcohol interacts with infliximab, but patients are advised that if they do decide to drink alcohol, they do so within the Department of Health guideline limits.


There is still limited evidence regarding the safety of taking infliximab during pregnancy. Researchers have found that although infliximab does not cross the placenta during the first two trimesters, it can do so during the third trimester. Due to a lack of clear evidence, drug manufacturers do not recommended the use of infliximab in pregnant women. On the other hand, some doctors believe that the treatment should be continued if it is keeping a pregnant woman’s condition in check, at least during the first and second trimester. Recent British Society of Gastroenterology guidelines suggest that doctors discuss the risk with pregnant women on an individual basis.


Research has suggested that it may be safe for mothers to breastfeed while taking this therapy because infliximab does not seem to pass into breast milk. However, evidence for this is still limited and most doctors do not advise breastfeeding during treatment or for six months since the last session of therapy.

Immunisations while on infliximab

Receiving certain vaccinations while receiving infliximab may be dangerous. Patients should not be given any “live” vaccines such as those used to immunize against rubella, TB, yellow fever or polio. However, inactivated vaccines such as those used for polio or influenza may be safe and patients should discuss with their doctor whether or not they can receive these vaccines.

Further Reading

Last Updated: Feb 24, 2023

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2023, February 24). Infliximab Safety. News-Medical. Retrieved on May 26, 2024 from

  • MLA

    Robertson, Sally. "Infliximab Safety". News-Medical. 26 May 2024. <>.

  • Chicago

    Robertson, Sally. "Infliximab Safety". News-Medical. (accessed May 26, 2024).

  • Harvard

    Robertson, Sally. 2023. Infliximab Safety. News-Medical, viewed 26 May 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How have inflammatory bowel disease treatments changed after the introduction of biologics?